Evaluation of the Immunological Efficacy of an LNP-mRNA Vaccine Prepared from Varicella Zoster Virus Glycoprotein gE with a Double-Mutated Carboxyl Terminus in Different Untranslated Regions in Mice
- PMID: 37766151
- PMCID: PMC10534744
- DOI: 10.3390/vaccines11091475
Evaluation of the Immunological Efficacy of an LNP-mRNA Vaccine Prepared from Varicella Zoster Virus Glycoprotein gE with a Double-Mutated Carboxyl Terminus in Different Untranslated Regions in Mice
Abstract
Cell-mediated immunity (CMI) plays a key role in the effectiveness of varicella zoster virus (VZV) vaccines, and mRNA vaccines have an innate advantage in inducing CMI. Glycoprotein E (gE) has been used widely as an antigen for VZV vaccines, and carboxyl-terminal mutations of gE are associated with VZV titer and infectivity. In addition, the untranslated regions (UTRs) of mRNA affect the stability and half-life of mRNA in the cell and are crucial for protein expression and antigenic translational efficiency. In this study, three UTRs were designed and connected to the nucleic acid sequence of gE-M, which is double mutated in the extracellular region of gE. Then, mRNA with different nucleic acids was encapsulated in lipid nanoparticles (LNPs), forming three LNP-mRNA VZV vaccines, named gE-M-Z, gE-M-M, and gE-M-P. The immune response elicited by these vaccines in mice was evaluated at intervals of 4 weeks, and the mice were sacrificed 2 weeks after the final immunization. In the results, the gE-M-P group, which retains the nucleic acid sequence of gE-M and is connected to Pfizer/BioNTech's BNT162b2 UTRs, induced the strongest humoral immune response and CMI. Because CMI is crucial for protection against VZV and for the design of VZV vaccines, this study provides a feasible strategy for improving the effectiveness and economy of future VZV vaccines.
Keywords: CMI; UTR; VZV; mRNA vaccine.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice.Int J Nanomedicine. 2024 Aug 6;19:8029-8042. doi: 10.2147/IJN.S464720. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39130684 Free PMC article.
-
LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice.Virol Sin. 2022 Oct;37(5):731-739. doi: 10.1016/j.virs.2022.06.002. Epub 2022 Jun 6. Virol Sin. 2022. PMID: 35671982 Free PMC article.
-
Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine.Pharmaceutics. 2022 Apr 30;14(5):973. doi: 10.3390/pharmaceutics14050973. Pharmaceutics. 2022. PMID: 35631559 Free PMC article.
-
Varicella-zoster virus: molecular controls of cell fusion-dependent pathogenesis.Biochem Soc Trans. 2020 Dec 18;48(6):2415-2435. doi: 10.1042/BST20190511. Biochem Soc Trans. 2020. PMID: 33259590 Free PMC article. Review.
-
VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study.Vaccine. 2019 Oct 16;37(44):6776-6781. doi: 10.1016/j.vaccine.2019.09.031. Epub 2019 Sep 19. Vaccine. 2019. PMID: 31543415 Review.
Cited by
-
Varicella zoster virus mRNA vaccine candidate induced superior cellular immunity and comparable humoral and Fc-mediated immunity compared to the licensed subunit vaccine in a mouse model.Hum Vaccin Immunother. 2025 Dec;21(1):2495607. doi: 10.1080/21645515.2025.2495607. Epub 2025 May 7. Hum Vaccin Immunother. 2025. PMID: 40331755 Free PMC article.
-
Research Progress on Varicella-Zoster Virus Vaccines.Vaccines (Basel). 2025 Jul 4;13(7):730. doi: 10.3390/vaccines13070730. Vaccines (Basel). 2025. PMID: 40733707 Free PMC article. Review.
-
A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses.NPJ Vaccines. 2025 Mar 14;10(1):49. doi: 10.1038/s41541-025-01093-1. NPJ Vaccines. 2025. PMID: 40087280 Free PMC article.
-
mRNA Vaccination: An Outlook on Innate Sensing and Adaptive Immune Responses.Viruses. 2024 Sep 1;16(9):1404. doi: 10.3390/v16091404. Viruses. 2024. PMID: 39339880 Free PMC article. Review.
-
Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice.Int J Nanomedicine. 2024 Aug 6;19:8029-8042. doi: 10.2147/IJN.S464720. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39130684 Free PMC article.
References
-
- Arruti M., Pineiro L.D., Salicio Y., Cilla G., Goenaga M.A., Lopez de Munain A. Incidence of varicella zoster virus infections of the central nervous system in the elderly: A large tertiary hospital-based series (2007–2014) J. Neurovirol. 2017;23:451–459. doi: 10.1007/s13365-017-0519-y. - DOI - PubMed
-
- Asada H., Nagayama K., Okazaki A., Mori Y., Okuno Y., Takao Y., Miyazaki Y., Onishi F., Okeda M., Yano S., et al. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain. J. Dermatol. Sci. 2013;69:243–249. doi: 10.1016/j.jdermsci.2012.10.015. - DOI - PubMed
-
- Gilbert P.B., Gabriel E.E., Miao X., Li X., Su S.C., Parrino J., Chan I.S. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J. Infect. Dis. 2014;210:1573–1581. doi: 10.1093/infdis/jiu279. - DOI - PMC - PubMed
Grants and funding
- 82104130/the National Natural Science Foundation of China
- 202301AT070362, 202201AU070150, and 202101AT070286/Yunnan Fundamental Research Projects
- 2022YFC2305700/the National Key R&D Program of China
- 202102AA310035/the Special Biomedicine Projects of Yunnan Province
- 202002AA100009/the Major Science and Technology Special Projects of Yunnan Province
- 3332022075/Fundamental Research Funds for the Central Universities
- H-2019063/Funds for the Training of High-Level Health Technical Personnel in Yunnan Province
- 202205AC160015/Funds for High-Level Scientific and Technological Talents Selection Special Project of Yunnan Province
- 2021-I2M-1-043/the CAMS Innovation Fund for Medical Sciences (CIFMS)
LinkOut - more resources
Full Text Sources
Research Materials